Objective-To assess exercise performance and resting left ventricular filling dynamics in patients with syndrome X (SX) in basal conditions and after 10 days treatment with oral atenolol. Design and patients-Exercise performance was studied and left ventricular filling assessed by Doppler-derived transmitral flow pattern analysis in 22 patients (16 female, mean (SD) age 53 (4) years) with angina, a positive exercise test, and angiographically smooth coronary arteries. Patients were studied after two 10 day treatment periods with either atenolol or placebo in a single-blind, randomised, crossover trial. The same protocol was followed in 10 patients with documented coronary artery disease (CAD) and in 13 controls (C). Results-Unlike the controls, patients with SX and those with CAD consistently showed exercise-induced ST segment abnormalities and impaired resting left ventricular filling while on placebo. Atenolol significantly reduced episodes of angina, completely prevented exerciseinduced ST segment changes in 18 SX patients, and delayed their onset in all patients with CAD: in both groups the agent significantly improved Dopplerderived indices (mean (SD)) of ventricular filling (E/A 0 97 (0.27) v 1-22 (0.32) and 0-84 (0.21) v 1 19 (0.37), respectively).
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Objective-To assess exercise performance and resting left ventricular filling dynamics in patients with syndrome X (SX) in basal conditions and after 10 days treatment with oral atenolol. Design and patients-Exercise performance was studied and left ventricular filling assessed by Doppler-derived transmitral flow pattern analysis in 22 patients (16 female, mean (SD) age 53 (4) years) with angina, a positive exercise test, and angiographically smooth coronary arteries. Patients were studied after two 10 day treatment periods with either atenolol or placebo in a single-blind, randomised, crossover trial. The same protocol was followed in 10 patients with documented coronary artery disease (CAD) and in 13 controls (C). Results-Unlike the controls, patients with SX and those with CAD consistently showed exercise-induced ST segment abnormalities and impaired resting left ventricular filling while on placebo. Atenolol significantly reduced episodes of angina, completely prevented exerciseinduced ST segment changes in 18 SX patients, and delayed their onset in all patients with CAD: in both groups the agent significantly improved Dopplerderived indices (mean (SD)) of ventricular filling ( Conclusions-The objective documentation of left ventricular filling abnormalities may be useful in confirming the clinical diagnosis of SX and in providing objective evidence of therapeutic benefit. The similarity of the symptoms and electrocardiographic and ventricular filling abnormalities found in patients with SX and in those with CAD suggests that ischaemia is involved in both groups. (Heart 1997; 77:32-39) Keywords: left ventricular filling; syndrome X; ,B blockers; diastolic function Syndrome X (SX) is a clinical definition that identifies patients with typical angina, a positive exercise test, and angiographically smooth epicardial coronary arteries.' Despite the considerable number of studies performed in recent years, the pathophysiology of this syndrome remains elusive, though most groups believe that abnormalities of the coronary microcirculation are involved.2- 6 Of the many aspects which have been investigated, those . Finally, we studied 13 subjects (nine women, mean age 52 (5) years, range 41-66) undergoing routine cardiological evaluation before general surgery. In all of them physical examination, chest x ray, resting and exercise ECG, and two dimensional echocardiographic and Doppler studies were normal. In all groups, subjects were age matched and had no diabetes, hypertension, overt left ventricular hypertrophy, pericardial or valve disease, or cardiomyopathy.
Each patient and control subject gave written informed consent to the study.
STUDY DESIGN
With the exception of coronary arteriography, which was obviously not performed in the controls without heart disease, the protocol was similar in all study subjects. After coronary Table 1 Resting heart rate (HR), systolic (SBP), and diastolic blood pressure (DBP) (mean (SD)) in syndrome X (SX), coronary disease patients (CAD), and controls on placebo (P), atenolol (A), and acute propranolol (AP) Doppler measurements were performed at rest, immediately after the study of wall motion at the end of exercise, again when the ECG and heart rate had returned to baseline, and after 4 and 24 hours. The apical four chamber view, optimised to visualise the left ventricular cavity and the maximal excursion of the mitral valve leaflets was used. The cursor line was positioned through a plane traversing the left ventricle from apex to mitral valve annulus. Care was taken in obtaining the smallest possible angle between the direction of diastolic blood flow and the orientation of the ultrasonic beam. The sample volume (5 mm in axial length) was positioned in the inflow area of the left ventricle between the mitral leaflet tips, and its position along the cursor line was adjusted until the highest early and late peaks of diastolic flow velocity were recorded and the graphic quality of the Doppler waveform was optimal. Table 2 Exercise variables (mean (SD)) in syndrome X (SX), coronary disease patients (CAD), and controls on placebo (P) and atenolol (A) 
Results

SYMPTOMS
During placebo 17 patients had a total of 75 attacks (mean 3A4 (2 2), range 0-6). Atenolol produced considerable symptomatic relief and 13 patients had no angina while four reported a marked improvement. Four patients complained of fatigue. The total number of anginal attacks was 14 (mean 0-6 (0 4), range 0-2, P < 0 003 v placebo).
Eight of the 10 patients with CAD had a total of 19 episodes of angina (mean 1-9 (06), range 0-4) during treatment with placebo. During treatment with atenolol five patients were asymptomatic and five reported a total of six episodes of chest pain (mean 0-6 (0 2), range 0-2, P < 0-02).
Finally, none of the 13 controls had symptoms during placebo treatment, though seven complained of fatigue while on atenolol.
RESTING HAEMODYNAMIC INDICES AND ECG
In the three groups resting heart rate and blood pressure were similar and were not significantly affected by placebo. In all three groups they were reduced by atenolol to a similar extent (table 1) .
On placebo, thirteen patients with SX and six patients with CAD exhibited repolarisation abnormalities such as flat or inverted T waves on the resting ECG. Nine patients with SX and four patients with CAD had completely normal ECGs on atenolol. Figure 3 Doppler mitralflow profiles in a syndrome Xpatient. Off therapy (A) there is a typical abnormal waveform, with EIA ratio < 1. After 10 days on atenolol (B) there is a marked increase ofpeak velocity in the rapidfilling phase and a decrease ofpeak velocity of atrial systole with a consequent normalisation of the EIA ratio. Despite a similar heart rate reduction no significant changes are observed after acute P blockade with propranolol (C).-EXERCISE TESTING All patients with SX or CAD had diagnostic ST segment depression during the exercise test performed on placebo. This was associated with chest pain in four (18%) and seven (70%) patients respectively.
On atenolol, 18 patients with SX and two patients with CAD did not develop diagnostic ECG changes with exercise. Angina occurred in three and one patients respectively. All controls had a negative exercise test, both off and on atenolol. Table 2 shows detailed ergometric results in the three groups.
ECHOCARDIOGRAPHY
The left ventricular mass index (LVMI) was 100 (18) g/m2 in SX patients, 122 (25) g/m2 in CAD patients, and 89 (18) g/m2 in controls. Both SX (P = 0 05) and CAD (P = 0004) patients had a greater LVMI than controls. A significant difference in LVMI was also found between CAD and SX patients (P = 0-01). No changes were observed after atenolol in all groups. Resting ejection fraction was 62 (9%) on placebo and 67 (6%) on atenolol (P = NS) in SX patients, 66 (12) v 63 (1 1 %) (P = NS) in CAD patients, and 70 (10) v 61 (13%) (P = 0 03) in normal controls. No resting or exercise-induced wall motion abnormalities were present in SX patients and normal controls.
On placebo, seven patients with CAD had resting abnormal wall motion in 2-5 (0 5) segments, which further deteriorated after exercise. Exercise-induced worsening of wall motion abnormalities was prevented by atenolol in five patients. The remaining three developed new wall motion abnormalities with exercise that were prevented by atenolol in two.
DOPPLER ECHOCARDIOGRAPHY
The mean values of the calculated variables are shown in table 3. Sixteen SX patients (70%) and nine CAD patients (90%) showed an abnormal (< 1) resting E/A ratio. On average, this variable was significantly lower in SX (P < 0-01) and CAD (P < 0-01) patients than in controls (figl). Although total transmitral flow was similar in the three groups, peak early diastolic flow velocity was less in SX (P < 0 005) and CAD (P < 0 005) patients than in controls. On placebo the time/velocity integrals of early and late diastolic flow were 9.5 (2 7) and 6-4 (1-3) cm in SX patients, 9 0 (3 2) and 7-8 (1.9) cm in CAD patients, and 12-9 (4.7) and 5-8 (2.2) in controls (P < 0-004 for both variables, CAD and SX v controls). Accordingly, the atrial contribution to total left ventricular filling was greater in SX (P < 0-03) and CAD (P < 0 004) patients than in controls (fig 2) . During chronic beta blockade the E/A ratio was within the normal limits in 18 SX patients and in six with CAD. However, although significantly better than during placebo treatment, this variable was still significantly lower in SX (P<0-05) and CAD (P<0-01) patients than in controls. The increment of the E/A ratio was determined by both an increase in E peak velocity and a decrease in peak A velocity. In controls, atenolol did not induce significant changes of the E/A ratio. time/velocity integrals of early and late diastolic flow also improved in SX and CAD patients but remained practically unchanged in controls. Accordingly, a greater reduction in the atrial contribution to left ventricular filling was observed in SX (P < 0-01) and CAD (P < 0 005) patients. Compared with placebo none of the above Doppler variables was significantly affected after acute propranolol administration in any of the study subjects (table 3) , despite a reduction in heart rate that was similar to that seen during long term treatment with oral atenolol (table 1, fig 3) .
Finally, exercise did not induce any significant change in the Doppler flow pattern in any of the three groups. Indeed, after the exercise test, (2 min, 10 min, 4 h, and 24 h) the E/A ratio did not change significantly and remained stable during the whole study period independently of the heart rate at which it was determined (fig 4) .
Discussion LEFT VENTRICULAR FILLING ABNORMALITIES IN SYNDROME X: COMPARISON W1TH PATIENTS WITH OBSTRUCTIVE CAD
Previous studies assessing left ventricular function in patients with chest pain and normal coronary arteries have reported conflicting results.2A [7] [8] [9] [10] [11] [12] A recent investigation failed to show measurable signs of left ventricular systolic dysfunction during or immediately after exercise, in spite of the occurrence of angina, ST segment depression, and occasionally lactate production.'2 Our results confirm the absence of abnormalities in regional wall motion both at rest and immediately after exercise, but show that most of the Doppler indices of resting diastolic function are frankly abnormal in most patients with syndrome X. Similarly, and in accord with previous observations,'5'8 resting left ventricular filling was also impaired in some patients with significant coronary artery disease. 
Left ventricular filling abnormalities may result from a variety of mechanisms: these include myocardial hypertrophy and fibrosis, which both affect ventricular compliance, 5 1719-21 and transient ischaemia, which impairs early diastolic relaxation and alters ventricular filling and the diastolic pressurevolume relation.22-25 However, in the absence of these conditions, and especially when systolic function is normal, impairment of diastolic function is difficult to explain.
In our study, patients with SX and CAD had significantly greater left ventricular mass than normal controls. In the absence of obvious ECG and echocardiographic signs of hypertrophy, this finding is hard to interpret: subtle fibrosis resulting from repetitive ischaemia causing a stiffer ventricle is a possible cause. However, whatever the mechanism, increased left ventricular mass does not appear directly to influence Doppler filling variables in trained athletes26 27 or patients with hypertension28 29 and hypertrophic cardiomyopathy. 30 Additionally, in our patients with SX and CAD, LVMI was not affected by atenolol, which, by contrast, markedly improved transmitral flow in most subjects. Therefore, the slight increase in LVMI that we observed in CAD and SX patients is unlikely to be the main determinant of the diastolic filling abnormalities that we found in our study.
Conversely, periods of myocardial ischaemia are known to produce changes in left ventricular relaxation and filling which may persist well beyond recovery of normal systolic function.3' 32 Therefore, repetitive periods of ischaemia that are asymptomatic and clinically inapparent may well have a cumulative effect and result in sustained alterations in left ventricular relaxation and filling. Certainly this could explain the impairment of left ventricular filling that we found in patients with coronary disease. It could also account for the alterations in left ventricular compliance that we recorded in patients with angina and angiographically normal coronary arteries-if their condition was at least partially a reflection of myocardial ischaemia. Diastolic Atenolol also improved left ventricular filling in patients with SX and in those with CAD. In the latter, the effect was probably due to the reduction of myocardial oxygen consumption improving the myocardial supply/demand ratio and preventing ischaemia.
A similar mechanism could also operate in patients with SX, though to a lesser extent. Furthermore, the possibility that, in both groups, this /,3 selective agent may have reduced a-mediated coronary vasoconstriction through a decrease of the overall sympathetic outflow to the heart cannot be completely disregarded. 40 Indeed, the pathophysiological role of the sympathetic nervous system in chronic stable angina is well established.42A4 The documented efficacy of /3 blockers3839 and the observed hypersensitivity of the coronary circulation to adrenergic stimuli40 suggests that increased sympathetic activity may well also play a significant pathophysiological role in the syndrome of angina and normal coronary arteries. In fact, adrenergic overactivity may cause excessive stimulation of both ,B and a receptors. The former increase myocardial demand, whereas the latter may limit the increase in coronary blood flow by causing arteriolar constriction.
It might be argued that the changes in transmitral Doppler flow velocities observed during treatment with atenolol could be simply attributed to the reduced heart rate, because a progressive reduction of the E/A ratio is observed when the heart rate is increased.45 However, the E/A ratio was stable at different heart rates in all study subjects, during both placebo and atenolol treatment (fig 4) . Furthermore, in patients with SX and in those with CAD acute ,B blockade by pro- Left ventricular diastolic function is a complex phenomenon, resulting from the intrinsic properties of the cardiac muscle, left ventricular systolic function, and the loading conditions of the ventricle. This has to be carefully considered when analysing diastolic indexes derived from the Doppler flow velocity waveform, a feature much influenced by several haemodynamic variables. Therefore, although our findings suggest that patients with syndrome X and coronary artery disease exhibit similar alterations of the diastolic filling velocity pattern, we cannot be certain that in both conditions these alterations are attributable to the same mechanism-namely, ischaemia. In using intravenous propranolol to correct for heart rate changes, we compared the acute administration of a non-selective ,B blocker with the long-term administration of a selective one. It is therefore not unconceivable that the observed differences between the two treatments may be not entirely due to the duration of P blockade but to the possible additional involvement of antagonism induced by propranolol. Finally, the atenolol-induced changes in resting transmitral flow pattern may depend on a rise in left atrial pressure. However, because atenolol did not cause any significant E/A changes in controls and improved symptoms and exercise tolerance in both SX and CAD groups, it is most unlikely that an increase in left atrial pressure could in itself be responsible for the observed trend towards normalisation of the transmitral flow pattern in the SX and CAD groups. Furthermore, the fact that acute treatment with propranolol did not induce any significant E/A ratio changes, is an additional challenge to the hypothesis that an increase in left atrial pressure could be the main determinant of the improvements seen after atenolol. 
